The COVID-19 pandemic continues to present challenges at every level—from its massive public health threat to its impact on the global economy.
In the midst of those challenges, Drs. Peter Hotez and Maria Elena Bottazzi at Texas Children’s Center for Vaccine Development are rapidly advancing work on vaccines that will protect against COVID-19 and other coronaviruses. Philanthropic support remains critical to their ability to proceed as quickly and efficiently as possible.
Texas Children’s Center for Vaccine Development has a successful track record of developing and advancing recombinant protein-based vaccines against neglected infections, including the coronaviruses SARS and MERS.
For the last six months, the research team at the Center for Vaccine Development has been using its extensive expertise with these related viruses to 1) forge new strategic global alliances and 2) accelerate the design, process, and evaluation of a vaccine that meets very important criteria.
We are committed to developing safe, low cost, easily administered, and rapidly scalable vaccines for the public good, including low- and middle-income countries.
In May 2020, Texas Children’s Center for Vaccine Development launched a partnership with PATH, a global nonprofit organization that is dedicated to improving public health and has expertise in advancing the development and licensure of affordable and effective vaccines, helping ensure their availability and accessibility for vulnerable populations.
In July 2020, Texas Children’s Center for Vaccine Development signed a non-exclusive license agreement with the industrial vaccine manufacturer, Biological E. Limited (BE), to advance and accelerate the technology transfer of the manufacturing processes.
We also will submit a comprehensive US regulatory package, ensuring that we receive valuable guidance about the development strategy and requirements needed to advance this vaccine into clinical studies safely and expeditiously.
Funding now will enable us to initiate clinical development activities in the United States and generate crucial data showing human safety, immunogenicity, and efficacy of the COVID-19 vaccine. This is an unprecedented opportunity to help save lives in our own community and around the world. Support our work by making a donation here.